The clinical relevance of Tks5 expression in cancer cells has been validated in various cancers, such as prostate cancer [18], breast cancer [16], and melanoma [19], which reported that Tks5 expression of cancer cells is correlated with the progression of carcinomas. Here, SH3PXD2A is linked to prostate carcinoma.